

MERCK LIMITED
Regd. Office: Shiveagar Estate 'A', Dr. Amte Besant Road, Worli, Mumbai - 400018
STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND THREE MONTHS ENDED 31ST MARCH, 2012

					(Rs. in Lakhs)					
Particulars		3 months ended 31/03/2012	Preceding 3 months ended 31/12/2011	Corresponding 3 months ended 31/03/2011 in the previous year	Previous year ended 31/12/2011	Segment Wise Revenue, Result and Capital Employed				
		Unaudited	Audited	Unaudited	Audited	Particulars	3 months ended 31/03/2012 Unaudited	Preceding 3 months ended 31/12/2011 Audited	Corresponding 3 months ended 31/03/2011 in the previous year Unaudited	Previous year ended 31/12/2011 Audited
1. Income from operations						1 Segment Revenue				
a) Net Sales/Income from operations (Net of excise duty)		13,673.57	12,656.71	11,526.17	55,757.08	a) Pharmaceuticals 8,811.30 8,092.47 8,415.76 38,946.61				
b) Other operating income		49.19	55.58	69.41	255.51	b) Chemicals 5,315.30 5,033.50 3,547.72 18,336.58				
Total income from operations (net)		13,722.76	12,712.29	11,595.58	56,012.59	Total 14,126.60 13,125.97 11,963.48 57,283.19				
2. Expenses						Less : Inter segment revenue 403.84 413.68 367.90 1,270.60				
a) Cost of materials consumed		3,995.19	3,493.63	3,797.04	16,953.81	Net Sales and Other Operating Income 13,722.76 12,712.29 11,595.58 56,012.59				
b) Purchases of stock-in-trade		2,791.04	3,732.11	2,112.86	11,318.40	2. Segment Results (Profit before Tax and Interest from each segment)				
c) Changes in inventories of finished goods,work-in-progress and stock in trade		(703.04)	(1,135.88)	(1,722.20)	(3,994.60)	a) Pharmaceuticals 713.97 (131.60) 827.33 4,010.58				
d) Employee benefits expense		2,276.80	2,103.51	1,854.22	8,127.19	b) Chemicals (Refer Note 4) 719.43 1,617.70 753.45 3,905.63				
e) Depreciation and amortisation expense		209.17	330.92	129.59	795.34	Total 1,433.40 1,486.10 1,580.78 7,916.21				
f) Other expenses		4,642.13	4,956.10	4,568.26	19,312.33	Less : i) Interest 0.61 0.38 0.48 1.62				
Total expenses		13,211.29	13,480.39	10,739.77	52,512.47	ii) Other un-allocable expenditure net off un-allocable Income (420.47) (405.00) (402.75) (1,644.00)				
3. Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)		511.47	(768.10)	855.81	3,500.12	Total Profit before Tax 1,853.26 1,890.72 1,983.05 9,558.59				
4. Other Income		1,342.40	1,231.20	1,127.72	4,632.09	3. Capital Employed				
5. Profit from ordinary activities before finance costs and exceptional items (3+4)		1,853.87	463.10	1,983.53	8,132.21	a) Pharmaceuticals 9,012.00 8,568.30 7,907.18 8,568.30				
6. Finance costs		0.61	0.38	0.48	1.62	b) Chemicals 12,771.12 11,448.00 6,201.92 11,448.00				
7. Profit from ordinary activities after finance costs but before exceptional items (5-6)		1,853.26	462.72	1,983.05	8,130.59	c) Unallocated 20,464.48 20,992.00 21,873.06 20,992.00				
8. Exceptional items (Refer Note 4)		-	1,428.00	-	1,428.00	Total 42,247.60 41,008.30 35,982.16 41,008.30				
9. Profit from ordinary activities before tax (7+8)		1,853.26	1,890.72	1,983.05	9,558.59					
10. Tax expense *		613.96	624.28	643.35	3,190.57					
11. Net Profit from Ordinary Activities after tax (9-10)		1,239.30	1,266.44	1,339.70	6,368.02					
12. Extraordinary Items (net of tax expense)		-	-	-	-					
13. Net Profit for the period (11±12)		1,239.30	1,266.44	1,339.70	6,368.02					
14. Paid-up equity share capital (Face Value Rs 10/-)		1,659.94	1,659.94	1,659.94	1,659.94					
15. Reserves excluding Revaluation Reserves as per balance sheet of		-	-	-	39,348.36					
16.i Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):										
(a) Basic		7.47	7.63	8.07	38.36					
(b) Diluted		7.47	7.63	8.07	38.36					
16.ii Earnings per share (after extraordinary items) (of Rs 10/- each) (not annualised):										
(a) Basic		7.47	7.63	8.07	38.36					
(b) Diluted		7.47	7.63	8.07	38.36					
A PARTICULARS OF SHAREHOLDING										
1 Public shareholding										
- Number of shares		8,000,158	8,000,158	8,000,158	8,000,158					
- Percentage of shareholding		48.2	48.2	48.2	48.2					
2 Promoters and Promoter Group Shareholding										
(a) Pledged/ Encumbered										
- Number of shares		-	-	-	-					
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)		-	-	-	-					
- Percentage of Shares (as a % of the total share capital of the company)		-	-	-	-					
(b) Non-encumbered										
- Number of shares		8,599,224	8,599,224	8,599,224	8,599,224					
- Percentage of shares (as a % of the total shareholding)		-	-	-	-					
- Percentage of Shares (as a % of the total share capital of the company)		51.8	51.8	51.8	51.8					
* Tax expense consists of:										
Current Tax		630.00	210.00	650.00	2,760.00					
Deferred Tax		(16.04)	414.28	(6.55)	430.57					
Particulars		3 months ended 31/03/2012								
B INVESTOR COMPLAINTS										
Pending at the beginning of the quarter		Nil								
Received during the quarter		1								
Disposed of during the quarter		1								
Remaining unresolved at the end of the quarter		Nil								
Notes :-										
1. The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 20th April, 2012. The above results were subjected to a "Limited Review" by the Statutory Auditors.										
2. Figures for the previous quarter/year have been re-grouped/re-arranged wherever necessary.										
3. Figures of the preceding 3 months ended 31st December, 2011 are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. Also the figures upto the end of the third quarter were only reviewed and not subjected to audit.										
4. During the previous year, the Company had reversed provision for impairment loss of Rs.1,428 Lakhs on a cash generating unit. This has been considered in the results of the Chemicals segment.										
Place : Mumbai						For MERCK LIMITED				
Date : 20th April, 2012						DR. M. DZIKI				
Please visit us at our website www.merck.co.in						MANAGING DIRECTOR				